Adriamycin and 1-(2-Chlorethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in the treatment of metastatic breast cancer
โ Scribed by William C. Waterfield; Charles K. Tashima; Gabriel N. Hortobagyi; George R. Blumenschein; Aman U. Buzdar; Michael A. Burgess
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 354 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The physiologic disposition of radioactive-labelled CCNU and MeCCNU was studied in patients receiving these drugs as part of their early clinical trial. CCNU was given orally in doses of 30-100 mg/m2 a n d MeCCNU in doses of 120-290 mg/m?. With both drugs, significant plasma levels of radioactivity
Forward mutations induced by 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the supF gene of Escherichia coli were recovered from bacteria deficient in nucleotide excision repair and in DNA-alkyltransferase activity. Bacteria were exposed to 0.4 mM CCNU (in vivo supF mutagenesis), increasing